secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0000950170-22-009935
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics reports Q1 net loss of $24.6M; FDA lifts clinical hold on CP101
--------------------------------------------------------------------------------

- FDA lifted clinical hold on CP101 IND; Phase 3 PRISM4 enrollment expected in H2 2022.
- Q1 2022 net loss $24.6M vs $14.0M in Q1 2021; revenue fell due to Takeda amendment.
- Secured $55M debt facility from Hercules Capital; $15M drawn at closing.
- Workforce reduced ~20% to focus on CDI, ASD, and Takeda-partnered IBD programs.
- Cash and equivalents $106.9M as of March 31, 2022; runway into Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022009935/0000950170-22-009935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022009935/fnch-20220516.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer